ArticleMolecular cancer2022
A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients.
Abstract readLetter
In one paragraph
Article in Molecular cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- HMHLVI: Hybrid Multi-view Hypergraph Learning with Variational Inference for snoRNA-Drug Association Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Article
- snoRNAs and their derived sdRNAs: Emerging regulators, biomarkers, and therapeutic targets in human cancers (Review).International journal of oncology · 2026Review
- Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status.Chinese medical journal · 2026Article
- Bisphosphate nucleotidase 1 promotes progression and docetaxel resistance in triple-negative breast cancer via STUB1-mediated destabilization of LIMA1.Cell death & disease · 2026Article
- Hepatitis virus-associated B cell non-Hodgkin's lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription.Scientific reports · 2026Article
- Small Nucleolar RNAs (snoRNAs) in Cancer: From Biogenesis to Clinical Potential.OncoTargets and therapy · 2026Review
- MeCP2 functions as a DNA methylation reader in immune homeostasis and cancer.Frontiers in epigenetics and epigenomics · 2026Review
- Review
- CLIC3 emerges as a novel prognostic biomarker and therapeutic target in triple-negative breast cancer through integrated multi-omics analysis.BMC cancer · 2025Article
- MYC/TET3-Regulated TMEM65 Activates OXPHOS-SERPINB3 Pathway to Promote Progression and Cisplatin Resistance in Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- GCNMF-SDA: predicting snoRNA-disease associations based on graph convolution and non-negative matrix factorization.Briefings in bioinformatics · 2025Article
- SNORA47 affects stemness and chemotherapy sensitivity via EBF3/RPL11/c-Myc axis in luminal A breast cancer.Molecular medicine (Cambridge, Mass.) · 2025Article
- SnoRNAs: The promising targets for anti-tumor therapy.Journal of pharmaceutical analysis · 2024Review
- U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the translocation of RPL23 from nucleoplasm to nucleolus and c-Myc expression.Breast cancer research : BCR · 2024Article
- Small nucleolar RNA and its potential role in the oncogenesis and development of colorectal cancer.World journal of gastroenterology · 2024Review
- Small but strong: the emerging role of small nucleolar RNA in cardiovascular diseases.Frontiers in cell and developmental biology · 2023Review
- SnoRNA and lncSNHG: Advances of nucleolar small RNA host gene transcripts in anti-tumor immunity.Frontiers in immunology · 2023Review
- iSnoDi-LSGT: identifying snoRNA-disease associations based on local similarity constraints and global topological constraints.RNA (New York, N.Y.) · 2022Article
- Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Biyun Wang *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, 270 Dong'an Road, Xuhui District, Shanghai, 200032, China.
Yannan Zhao *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, 270 Dong'an Road, Xuhui District, Shanghai, 200032, China.
Yi Li *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, 270 Dong'an Road, Xuhui District, Shanghai, 200032, China.
Yingying Xu *NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai, 200032, China.
Yun ChenSchool of Public Health, Key Laboratory of Public Health Safety, NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China.
Qiuyu JiangNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai, 200032, China.
Dingjin YaoNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai, 200032, China.
Li ZhangNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai, 200032, China.
Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, 270 Dong'an Road, Xuhui District, Shanghai, 200032, China. xchu2009@hotmail.com.
Chaowei FuSchool of Public Health, Key Laboratory of Public Health Safety, NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China. fcw@fudan.edu.cn.
Si ZhangNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai, 200032, China. zhangsi@fudan.edu.cn.
She ChenNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai, 200032, China. shechen@fudan.edu.cn.ORCID 0000-0002-4077-1649
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
RNA, Small NucleolarBiomarkers, TumorCell Line, TumorGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansPrognosisTriple Negative Breast NeoplasmsBiomarkers, TumorRNA, Small NucleolarBreast cancerChemoresistanceMeCP2PlatinumPrognostic biomarkerSNORD33
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.